期刊
BLOOD
卷 120, 期 9, 页码 1782-1790出版社
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2012-05-402784
关键词
-
类别
资金
- Ministerio de Sanidad y Consumo (RTICC)
- Asociacion Espanola contra el Cancer (AECC)
- Ministerio de Ciencia e Innovacion, Spain [SAF 2008-03 871, FI08/00 038]
- Contract Miguel Servet from Fondo Investigaciones Sanitarias
There is a demand to understand B-cell lymphoma pathogenesis better, to identify new markers, and to define multiple lymphoproliferative disorders more accurately. MicroRNAs (miRNAs) are regulators of protein translation, comprising a group of more than 1500 short noncoding single-strand RNA molecules of approximately 22 nucleotides in length. They are easily detectable in fresh or paraffin-embedded diagnostic tissue and serum. Expression of individual miRNAs and miRNA signatures allows specific cell-differentiation stages to be identified, and is a powerful diagnostic and prognostic method. Here we review what is known about the pathogenic relevance of miRNAs, and use of miRNAs for the diagnosis and prognosis of B-cell lymphomas. Most of the published data concern chronic lymphocytic lymphoma and diffuse large B-cell lymphoma, and implicate miRNAs in the pathogenesis of these diseases. They identify miRNAs that could be used for diagnosis, prognosis, or prediction of response to specific therapies. (Blood. 2012;120(9):1782-1790)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据